I’ve heard of the drug issue but that is an interesting theory you bring up regarding human cells.
1 Like
Did a quick search on the topic:
What Kiriakou actually said.
A YouTube clip shows former CIA officer John Kiriakou telling Tucker Carlson that a DEA contact told him U.S. officials allowed Afghan heroin production because most of it flowed to Russia and Iran “by design.” This is the source of the statement you’re asking about. YouTube
However, this is Kiriakou’s recounting of a conversation, not a documented CIA policy.
What credible reporting shows.
Authoritative reporting from The Washington Post and NPR describes something very different:
• The CIA ran a covert program to weaken Afghanistan’s poppy crop, dropping genetically modified poppy seeds designed to reduce heroin potency.
This program ran roughly from 2004–2015.
• The U.S. government viewed Afghan opium as a strategic problem, because heroin profits funded the Taliban and undermined the Afghan government the U.S. was supporting.
These sources directly contradict the idea that the U.S. was trying to increase poppy production.
Does any evidence support the “hook Russia and Iran on heroin” theory?
No publicly available evidence supports this:
• No declassified documents
• No congressional testimony
• No investigative reporting
• No statements from other intelligence officials
The only known source for this claim is Kiriakou’s anecdote about what a DEA contact allegedly told him. That is not independently verified.
4 Likes
I actually did watch an interview on a fringe web site a few years ago by some scientist who worked on the discovery of AIDS in the 80s and claimed that HIV didn’t turn into AIDS and that they’re two separate diseases and that is how you can explain why people who get HIV don’t die anymore. He sounded sincere and credible but I have no idea if it’s true. It’s probably not true.
2 Likes
They don’t die anymore because of potent antiviral medication.
3 Likes
Hey RapAdmin, did you find a reliable source ? You tested it ?
1 Like
No, its not high on my priority list right now.
1 Like
Its in my list pretty high. If get it - will share my experience
I think its very interesting and haven’t many downsides.
3 Likes
Which medication are we talking about here? sorry lost track of the med’s name?
1 Like
Descovy. But its the pricey original.
I’m looking for the generics. Tafero EM, and a lot of others.
Tafero-EM — Hetero
Taficita — Mylan/Viatris
Tafmune EM — Cipla
Dobataf EM — Aurobindo
Tafnat EM — Natco
Emtaf — Emcure
Alafevir EM by Louras Labs - this is what I chose.
3 Likes
Wow… fascinating how subtle changes in environmental conditions can change a combination of equal elements in every way. But in hindsight, maybe not surprised. Like heat or cold on water… a gas, a liquid and a solid… but the same compound. Thanks.
3 Likes
Thanks for the info. Let us know how it goes when you had the chance to try it for a week or two.
3 Likes
Can confirm that price of 20$ for 30 days for Tafero-EM from a seller. Even got a quote for 45$ for 90 pills from another one.
1 Like
The Indian generic formulations of the combined is for sale only in India. I can get the TAF which isn’t restricted for export. My question is - will the TAF alone be the same given its what is doing the heavy lifting?
Gemini answered:
Yes, TAF alone has a distinct therapeutic target, and it does not strictly need to be combined with FTC to function.
1. The Cellular Target is Independent of FTC
The biological mechanism behind the geroprotective theory targets retrotransposon reverse transcriptase activity (such as LINE-1 elements).
- How TAF works: Inside cells, TAF is metabolized into its active form, tenofovir-diphosphate (TFV-DP). This active molecule acts as a nucleotide reverse transcriptase inhibitor (NRTI). It tricks the reverse transcriptase enzymes (used by both HIV and mammalian retrotransposons) into incorporating it into replicating DNA chains, which halts their replication entirely.
- The Role of FTC: Emtricitabine (FTC) is simply another type of NRTI that targets reverse transcriptase in a similar, yet complementary, manner.
2. Why the Study Used FTC/TAF
The study utilized a combination of FTC/TAF (200 mg/25 mg) because it analyzed biobanked samples from existing, FDA-approved clinical trials. In clinical practice, these two drugs are almost always packaged together (such as in the brand-name drug Descovy) because dual-therapy is mandatory to prevent drug resistance when treating or preventing HIV.
3. TAF Alone as a Standalone Product
The product shown in image.png is TAFNEXT 25 mg, which is single-agent TAF.
- As a standalone drug, TAF 25 mg is globally FDA-approved and prescribed under the brand name Vemlidy for the treatment of Chronic Hepatitis B Virus (HBV).
- Because HBV replicates using a reverse transcriptase enzyme, TAF effectively suppresses the virus all on its own without needing to be paired with FTC.
Summary
The biological “machinery” that the researchers are trying to block to reduce biological aging belongs entirely to the reverse transcription process. Because TAF independently inhibits this process, it possesses the standalone pharmacology required to hit that target. However, because human longevity data only exists for the combination formulation so far, we cannot yet clinically state whether TAF alone would replicate the exact epigenetic age-reduction results seen in the study.
2 Likes
Low AdaptAge and High DamAge is bad right
1 Like
Gemini says:
Yes, your biological intuition is completely spot on.
Why Low AdaptAge and High DamAge is Bad
In the framework of these specific “causality-enriched” epigenetic clocks (pioneered by researchers like Kejun Ying and Vadim Gladyshev):
- DamAge tracks harmful, detrimental DNA changes that accumulate as we age. A high DamAge score is strongly associated with adverse health conditions and increased mortality risk.
-
AdaptAge tracks the body’s protective, beneficial adaptations attempting to combat that aging. A low AdaptAge score means the body is failing to mount a proper protective response.
Therefore, having high damage and low adaptation is exactly what defines a accelerated, unhealthy state of biological aging.
Does the TAF Study Show This Result?
No, the study actually shows the exact opposite (positive) result.
The preprint study you provided evaluated whether taking the drug regimen containing TAF could improve biological age markers. When looking at the data from the abstract:
- PhenoAge decreased (−6.33, p=0.008): This indicates that the participants’ general biological age markers significantly dropped after the 12 weeks of therapy.
-
DunedinPACE decreased (−0.061, p=0.019): DunedinPACE measures the pace of aging (how fast your biological clock is ticking). A decrease means the participants’ rate of cellular aging slowed down.
While the specific subset clocks “DamAge” and “AdaptAge” are not explicitly named in the brief abstract text, the authors state there were “concordant reductions across additional systems-specific epigenetic clocks.” In the context of a successful gerotherapeutic effect, a positive outcome means DamAge goes down (less damage) and the overall biological age pressure is relieved.
To learn more about how these specific causality clocks work and how they differentiate between damage and adaptation in anti-aging research, you can check out this Interview on Causal Epigenetic Aging Clocks featuring one of the lead developers of the DamAge and AdaptAge models.
study show
AdaptAge -5.92
DamAge +2.10
which is negative result
does AdpatAge also decrease if you get younger?
if so omega-3 AdaptAge +6 and DamAge -6
how do we interutp this results
doi:10.3389/fgene.2026.1836446
Turning back time: a comprehensive list of interventions that decrease next-generation epigenetic aging clocks in humans
Has anyone taken Descovy for any length of time and had positive measurable results?
It’s no more expensive from India than some of the common supplements that I take. It is a drug if taken must be taken for life to achieve maximum results.
Gemini Pro 3.1:
Do the Benefits Remain After Discontinuation?
No. The geroprotective effects are entirely dependent on continuous use.
Descovy does not permanently edit or silence the genome; it acts as a chemical blockade. The active intracellular metabolite (tenofovir diphosphate) physically binds to and inhibits the reverse transcriptase enzyme utilized by LINE-1 retrotransposons.
If the drug is discontinued, intracellular drug levels decline, and the reverse transcriptase is freed to operate again. LINE-1 will resume leaking cDNA into the cytoplasm, the cGAS-STING pathway will detect the anomaly, and the resulting sterile inflammation will return. To maintain the reduction in biological age markers, the molecular suppression must be continuous.
I think the first step on this program is to see if we get the same decrease in epigenetic age that they did in the study.
After that I would start digging deeper into the issue of biological benefits and dosing schedules.
1 Like